ncRNA basic information
ncRNA ID:
MI0000285
ncRNA Database:
miRBase
ncRNA Name:
miR-205
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
NA
ncRNA Pathway:
ERK pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The aim of the present study was to investigate the potential roles of UTMD-mediated miRNA (miR)-205 delivery in the development of prostate cancer (PCa). In the present study, miR-205 expression was examined by reverse transcription-quantitative polymerase chain reaction assay. miR-205 mimics were transfected into PC-3 cells using the UTMD method, and the PC-3 cells were also treated with cisplatin. Cell proliferation, apoptosis, migration and invasion abilities were detected using Cell Counting kit-8, flow cytometry, wound healing and Transwell assays, respectively. In addition, the protein expression levels of caspase-9, cleaved-caspase 9, cytochrome c (cytoc), epithelial (E)-cadherin, matrix metalloproteinase-9 (MMP-9), phosphorylated (p)-extracellular signal-regulated kinase (ERK) and ERK were measured by western blot analysis.
Drug Response:
sensitive
Cancer basic information
Cancer:
prostate cancer
Tissue/Cell:
cell line (RWPE-1,VCaP, LNCaP, PC-3, and DU145)
Other information
Title:
Ultrasound-targeted microbubble destruction-mediated miR-205 enhances cisplatin cytotoxicity in prostate cancer cells.
Journal:
Mol Med Rep
Published:
2018
PubMed ID:
30066866